Record number:
307
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
Most recent risk assessment for neuroendocrine tumors (including high grade neuroendocrine carcinomas, low(er) grade neuroendocrine tumors, carcinoid tumors, pheochromocytomas and paragangliomas) (Council of Europe, 2022):
Due to their potential for undetected metastasis, high-grade neuro-endocrine carcinomas are an unacceptable risk for organ donation. Insufficient information exists to guide practice for neuro-endocrine tumours, carcinoid tumours, phaeochromocytomas and paragangliomas. In the case of critically ill recipients, these tumours might be acceptable after a careful individual risk–benefit analysis. Neuro-endocrine tumours in the donor history: No data are available from the literature. Due to this and their potential for undetected metastasis, treated high-grade neuro-endocrine neoplasms in the donor history are classified as high risk for organ donation. In the case of a previous history (> 5 years) of neuro-¬endocrine tumours (carcinoid tumours, phaeochromocytomas and paragangliomas) without any kind of disease recurrence or progression, donors should be considered high risk in the absence of sufficient information to guide practice.
Time to detection:
13 months
Alerting signals, symptoms, evidence of occurrence:
Not specified. Small cell malignancy identified.
Demonstration of imputability or root cause:
Liver and two kidneys transplanted. Two recipients from the same donor reported to be affected.
Imputability grade:
2 Probable
Groups audience:
Suggest new keywords:
Registry series
Liver transplant
Kidney transplant
Malignancy
Suggest references:
aaa
Expert comments for publication:
Part of a registry series report. Since 2 of three recipients from this donor developed similar tumor, it is highly likely that this represents a donor transmitted neoplasm.